Follow us on Bluesky
Bluesky · Hashtag

#ASCO26

19
posts · 30d
8
users
1
posts / day
2.4
posts / user
-100% vs last week

#ASCO26 is an active hashtag on Bluesky. In the last 30 days, 8 people shared 19 posts with it — around 1 a day. Activity is down 100% versus the previous week, peaking on Jul 28 with 4 posts.

#ASCO26 posts per day (last 30 days)

Related tags

Tags most often used together with #ASCO26.

#oncology 9

Posts with #ASCO26

NEJM.org
@nejm.org
2 months ago
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM #ASCO26
Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
1 30 50
American Society of Clinical Oncology
@ascocancer.bsky.social
2 months ago
The final study presented at #ASCO26 Plenary: RASolute-302 results show daraxonrasib meeting all primary and key secondary endpoints, demonstrating significant and clinically meaningful improvements in OS, PFS, and ORR in metastatic #PDAC: bit.ly/49r62n1 #ASCODailyNews
0 5 14
NEJM.org
@nejm.org
2 months ago
Among patients with 𝘙𝘌𝘛 fusion–positive non–small-cell lung cancer, adjuvant selpercatinib led to longer event-free survival than placebo. Adverse events of grade 3 or higher included elevated liver-enzyme levels. Full phase 3 LIBRETTO-432 trial results: nej.md/3Q3QcIo #ASCO26
Graph depicting survival rates over time for patients using selpercatinib versus a placebo in early-stage RET fusion-positive non-small-cell lung cancer. The x-axis shows months since randomization, and the y-axis represents the percentage of patients. The logo for the New England Journal of Medicine is present.
0 3 13
ASCO Palliative Oncology Community of Practice (PallOncCoP)
@pallonccop.bsky.social
3 months ago
1 week left to go. Will you be there? #pallonc #supponc #ASCO26 @crisbergerot.bsky.social @realbowtiedoc.bsky.social @tingtingzhang.bsky.social @fionnualacrowley.bsky.social @ericroeland.bsky.social @mazietsangmd.bsky.social @ascocancer.bsky.social @darcyburbage.bsky.social @rsedhom.bsky.social

Join us for our **Live Meeting** @ascocancer.bsky.social on Saturday May 30th 4:30-6p CST Room E253cd #ASCO26 @realbowtiedoc.bsky.social @darcyburbage.bsky.social @crisbergerot.bsky.social @tingtingzhang.bsky.social @fionnualacrowley.bsky.social @ericroeland.bsky.social
1 6 10
NEJM.org
@nejm.org
2 months ago
In NSCLC with 𝘌𝘎𝘍𝘙 exon 20 insertions, first-line sunvozertinib led to longer progression-free survival than chemotherapy. The most common adverse events of grade 3 or higher were elevated creatine kinase, diarrhea, and anemia. Full phase 3 WU-KONG28 trial results: nej.md/4fQWMwa #ASCO26
A Kaplan-Meier graph from the Original Article "First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations," which is being published in conjunction with a presentation at ASCO. The graph compares progression-free survival rates between sunvozertinib and chemotherapy for NSCLC with EGFR Exon 20 insertion mutations. Statistical details and a logo for the New England Journal of Medicine are present at the bottom.
1 3 10
NEJM.org
@nejm.org
2 months ago
Phase 3 MajesTEC-9 trial: In relapsed multiple myeloma, teclistamab improved 18-month progression-free survival as compared with standard therapy. Grade 3 or 4 infections were common; antimicrobial prophylaxis and immune globulin support were recommended. nej.md/3PvpJDr #ASCO26
Kaplan–Meier estimates of progression-free survival among patients who had been randomly assigned to receive either teclistamab or the investigator’s choice of pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd) (intention-to-treat population). The x-axis marks months since randomization, while the y-axis indicates the percentage of patients. The New England Journal of Medicine logo is at the bottom.
1 4 9
Liz Highleyman
@lizhighleyman.bsky.social
about 2 months ago
News from #ASCO26. Personalized mRNA melanoma vaccine shows durable benefit at 5 years. This follows news at #AACR26 that a pancreatic cancer vaccine lowers recurrence risk at 6 years. mRNA technology looks like a winner for reducing cancer relapse. www.cancerhealth.com/arti….
Personalized Melanoma Vaccine Cuts Relapse Risk at 5 Years

www.cancerhealth.com

Personalized Melanoma Vaccine Cuts Relapse Risk at 5 Years

Adding a customized mRNA vaccine to checkpoint immunotherapy was associated with a 49% lower risk of melanoma recurrence or death.
1 3 9

Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.

View all posts on Bluesky

Explore trending tags

#art #oc #nsfw #furry #digitalart #artfight #furryart #fanart #artfight2026 #AI #photography #fcf
Back to all tags